Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs BIO-TECHNE Corp — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $31.51, while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| NVDL | TECH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $72.12 |
52-Week Low | $21.76 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
